15 nominees · 3 ballot items.
Election of Directors; Advisory vote to approve executive compensation (Say-on-Pay); Ratification of Deloitte & Touche LLP as independent auditors.
Election of the board-nominated slate of directors for both PG&E Corporation and Pacific Gas and Electric Company, with nominees to hold office until the 2027 annual meeting.
Non-binding, advisory vote (Say-on-Pay) to approve the 2025 compensation of named executive officers as disclosed in the proxy statement, including CD&A.
The proposal requests an advisory approval of the 2025 executive compensation program for PG&E Corporation and the Utility, as described in the Compensation Discussion and Analysis and related disclosure. Management seeks this non-binding shareholder vote to confirm that its pay programs appropriately tie a significant portion of executive pay to both short-term and long-term performance metrics emphasizing safety, customer outcomes, and financial stability, and to demonstrate alignment with shareholders and regulatory commitments (including AB 1054 and POR OII). The Board and the People and Compensation Committee recommend a vote FOR, arguing that the 2025 program had high at-risk pay, appropriate weighting toward safety and customer metrics, and governance measures (independent consultant, clawbacks, ownership guidelines) to mitigate excessive risk-taking. The proxy provides detailed metrics and outcomes for STIP and LTIP awards, shows that short-term incentive payout was 139% of target based on certified metrics, and discloses PSU results and changes to relative TSR methodology to address company-specific market impacts. Shareholders’ advisory vote is non-binding; if not approved, the Committee will consider feedback in future compensation design.
Ratify Deloitte & Touche LLP as the independent auditor for PG&E Corporation and Pacific Gas and Electric Company for the 2026 fiscal year.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 6.41% | 141,063,546 | $2.5B |
| 2 | STATE STREET CORP | 5.72% | 125,873,456 | $2.2B |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.95% | 109,073,619 | $1.9B |
| 4 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 3.92% | 86,392,242 | $1.5B |
| 5 | AQR CAPITAL MANAGEMENT LLC | 3.81% | 83,840,538 | $1.5B |
| 6 | BlackRock, Inc. | 3.58% | 78,877,610 | $1.4B |
| 7 | FMR LLC | 3.51% | 77,234,733 | $1.4B |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.63% | 57,879,624 | $1.0B |
| 9 | BlackRock, Inc. | 2.25% | 49,471,728 | $869M |
| 10 | DEUTSCHE BANK AG\ | 1.60% | 35,326,704 | $621M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.